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OBJECTIVE
Type 2 diabetes mellitus (DM) has been associated with lung dysfunction, but this
association has not been explored in Hispanics/Latinos. The relation between
diabetic nephropathy and lung function and symptoms has not been explored.
RESEARCH DESIGN AND METHODS
The Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a large, mul-
ticenter, observational study, recruited 16,415 participants aged 18–74 years
(14,455 with complete data on variables of interest), between 2008 and 2011 from
four U.S. communities through a two-stage area household probability design.
Baseline measurements were used for analyses. Forced expiratory volume in 1 s
(FEV1), forced vital capacity (FVC), and dyspnea score were compared between
individuals with and without DM, overall, and stratified by albuminuria. The
analyses were performed separately for those with and without preexisting lung
disease (chronic bronchitis, emphysema, asthma). Linear regression with sam-
pling weights was used for all analyses.
RESULTS
Among Hispanics/Latinos without lung disease, those with DM had lower mean
FEV1 and FVC values and a higher mean dyspnea score than those without DM
(mean [95% CI] FEV1 3.00 [2.96–3.04] vs. 3.10 [3.09–3.11] L, P < 0.01; FVC 3.62
[3.59–3.66] vs. 3.81 [3.79–3.83] L, P < 0.001; dyspnea score 0.60 [0.49–0.71] vs.
0.41 [0.34–0.49], P < 0.001). Hispanics/Latinos with DM and macroalbuminuria
showed 10% lower FVC (P < 0.001), 6% lower FEV1 (P < 0.001), and 2.5-fold higher
dyspnea score (P = 0.04) than those without DM and with normoalbuminuria.
Similar findings but with higher impairment in FVC were found in Hispanics/
Latinos with lung disease.
CONCLUSIONS
Hispanics/Latinos with DM have functional and symptomatic pulmonary impair-
ment that mirror kidney microangiopathy. The progression of pulmonary impair-
ment in adults with DM needs to be investigated further.
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Prior epidemiological (1–3) and clinical
studies (4–6) have shown that non-Hispanic
whites and blacks with type 2 and type 1
diabetes mellitus (DM) have lower pul-
monary function (i.e., forced expiratory
volume in 1 s [FEV1], forced vital capacity
[FVC], and diffusing capacity of lung for
carbon monoxide [DLCO]) than those
without DM. Some of these studies found
that lung dysfunction correlates with DM
control, duration, andmicrovascular com-
plications (1,4,5).
We summarized the results of these
studies in a qualitative review (7). With
respect to the magnitude of lung dys-
function, a meta-analysis found that
FEV1, FVC, and DLCO are 5–10% lower
in adults with DM than in those without
DM (8). None of the prior cohort stud-
ies evaluated the association between
DM and lung dysfunction in Hispanics/
Latinos (1–3). Hispanics/Latinos have a
higher prevalence of DM (9), poorer
DM control (10), and higher prevalence
and faster progression of microvascular
complications (11) than other popula-
tions. In this context, we believe it im-
portant to evaluate whether Hispanics/
Latinos with DM present lung dysfunc-
tion and to assess the degree of this pul-
monary impairment.
Lung dysfunction has been associated
with DM, but whether this association
has clinical consequences, such as dyspnea,
is unknown. Adults with DM are more
likely to have cardiac diseases, such as
coronary artery disease (CAD) and con-
gestive heart failure, leading to dyspnea.
Therefore, one can expect that adults
with DM aremore likely to have dyspnea
than adults without DM. Whether the
dyspnea is solely due to heart disease
or whether lung dysfunction associated
with DM can also contribute to dyspnea
has not been studied. Lung diseases,
such as asthma, chronic bronchitis, and
emphysema, and DM have a high prev-
alence and are likely to coexist in the
population (12–14), yet the impact of
DM on lung function in adults with pre-
existing lung disease has not been stud-
ied. This can be important in the context
of increasing overall morbidity andmor-
tality from lung diseases (15).
The mechanisms that explain the
association between DM and lung dys-
function remain unknown. One potential
pathway provided by experimental (16,17)
and autopsy (18) studies demonstrated
glycosylation of the lung tissue collagen
and proteins, leading to interstitial fibrosis
and alveolar capillary microangiopathy. If
lung microangiopathy is responsible for
the impairment in lung function observed
in DM, it is reasonable to expect that this
impairment correlates with other DM mi-
crovascular complications, such as diabetic
nephropathy.
In this study, we evaluatedwhether 1)
Hispanics/Latinos with DM present func-
tional and symptomatic pulmonary im-
pairment, 2) the pulmonary impairment
associated with DM is present in adults
without and with preexisting lung dis-
ease, and 3) the pulmonary impair-
ment associated with DM correlates
with albuminuria.
RESEARCH DESIGN AND METHODS
Participants
The design and conduct of the Hispanic
Community Health Study/Study of Lati-
nos (HCHS/SOL) have been described
previously (19). The HCHS/SOL is a pro-
spective cohort study of 16,415men and
women who self-identified as Hispanic/
Latino (of Cuban, Dominican, Puerto
Rican, Mexican, Central American, or
South American origin) and were aged
18–74 years at baseline. Participants
were recruited through a multistage
probability sample design from defined
communities in the Bronx, New York;
Chicago, Illinois; Miami, Florida; and
San Diego, California (20). The first stage
was a stratified random sample of cen-
sus block groups, and the second was a
separate stratified sample of household
addresses within the first stage. House-
hold members were then screened and
sampled from the selected household
addresses. Sampling weights were es-
tablished based on the probability of se-
lection, adjustment for nonresponse,
trimming to handle extreme values of
the weights, and calibration to the
known population distribution and nor-
malized to the entire HCHS/SOL target
population.
The analyses of the current study are
based on the baseline examination. Of
the 16,415 participants, 1,960 were ex-
cluded due to missing data on lung func-
tion measures, FEV1, and FVC (n = 806);
history of asthma or chronic obstructive
pulmonary disease (n = 77); albumin-to-
creatinine ratio (ACR) (n = 773); dyspnea
questionnaire (n = 3); or other covariates
(n = 301), leaving a sample of 14,445 for
analyses, including 11,496 participants
without DM and 2,959 with DM at
baseline.
Assessments and Outcome Measures
The definitions and methods used for
baseline measurements have been pre-
viously described (19). Details on the
laboratory collection, processing, and
analysis can be found in the laboratory
manual (20).
Participants were asked to fast for at
least 8 h before the examination. They
were classified as having DM if any of
the following American Diabetes Associ-
ation criteria were met: 1) fasting
plasma glucose (FPG) $126 mg/dL, 2)
post–oral glucose tolerance test plasma
glucose level$200 mg/dL, and 3) glyco-
sylated hemoglobin (HbA1c) $6.5%. In
addition to the laboratory test criteria,
DMwas defined based on current use of
antidiabetic medications or self-report.
The definitions and methods used for
other baseline measurements (age,
sex, Latino background, height, waist
circumference [WC], cumulative smok-
ing) have been previously described
(19). Lung disease (chronic bronchitis,
emphysema, asthma) was defined based
on self-report. In addition, standard dig-
itized spirometric measurements of
timed pulmonary function (FEV1, FVC)
were performed based on Epidemiology
Standardization Project (21) and Ameri-
can Thoracic Society (22) recommenda-
tions by using a SensorMedics model
1022 dry-rolling seal volume spirometer
(CareFusion, Yorba Linda, CA). Themeth-
odology was standardized across the
four field centers, and quality control
and reproducibility were coordinated
by a centralized pulmonary function
reading center.
Heart failure (HF) was defined based
on self-report. CAD was defined based
on electrocardiograms of possible old
myocardial infarction and/or self-report
of heart attack or procedure (angio-
plasty, stent, coronary artery bypass).
Fasting albumin and creatinine were
measured in urine samples collected
at the beginning of the examination.
Normoalbuminuria was defined as
ACR ,30 mg/g. Microalbuminuria was
defined as ACR in the range of 30–300
mg/g, and macroalbuminuria was de-
fined as ACR.300 mg/g. C-reactive pro-
tein (CRP) along with other blood tests
weremeasured in a fasting blood sample
collected at the study visit.
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Dyspnea score was calculated simi-
larly to other validated instruments
(23) based on the following questions:
1) Are you troubled by shortness of
breath when hurrying on level ground
or walking up a slight hill? 2) Do you
have to walk slower than people of
your age on level ground because of
shortness of breath? 3) Do you ever
have to stop for breath when walking
at your own pace on level ground? 4)
Do you ever have to stop for breath after
walking about 100 yards (or after a few
minutes) on level ground? 5) Are you
too short of breath to leave the house
or short of breath on dressing or un-
dressing? If the participants responded
negatively to the first question, then the
dyspnea score was 0. If they responded
affirmatively to the first question, then
the dyspnea score was the maximum of
the ordered questions (question 1 =
1 point, question 2 = 2 points, question
3 = 3 points, question 4 = 4 points, ques-
tion 5 = 5 points) because the partici-
pants’ answers represented the extent
to which they perceived breathlessness
to affect their mobility.
Statistical Analysis
Cross-sectional analyses were per-
formed to compare FEV1, FVC, and
dyspnea score in participants with and
without DM. Analyses were performed
separately for participants without and
with lung disease. A separate model
testedwhether the association between
DM and lung measures was indepen-
dent of systemic inflammation (CRP).
For individuals with DM, the correla-
tions between FEV1, FVC, and dyspnea
score and DM control (HbA1c) and sever-
ity (ACR) were evaluated separately for
participants without and with lung dis-
ease. To further explore the association
between lung function and albuminuria,
participants with DM were stratified by
ACR (normoalbuminuria, microalbumin-
uria, and macroalbuminuria), and the
mean FEV1, FVC, and dyspnea score for
each group were compared with the
group without DM and with normoalbu-
minuria (reference).
All analyses were weighted to ad-
just for sampling probability and non-
response. Descriptive characteristics
were computed for all participants
stratified by lung disease and DM sta-
tus. The means of lung measures were
calculated by lung disease and DM sta-
tus. Survey-specific procedures were
used to calculate 95% CIs to account
for the two-stage sampling design,
stratification, and clustering. Baseline
characteristics were computed and
compared using t tests for continuous
variables and x2 tests for categorical
variables.
Table 1—Baseline participant characteristics (N = 14,455)
Without lung disease (n = 11,810) With lung disease (n = 2,645)
Characteristic Non-DM (n = 9,510) DM (n = 2,300) Non-DM (n = 1,986) DM (n = 659)
Age (years) 38.5 (38.0–39.0) 53.7 (52.8–54.6) 39.3 (38.4–40.2) 53.8 (52.3–55.2)
Female (%) 50.1 (48.9–51.4) 52.3 (51.7–53.0) 58.2 (55.8–60.6) 63.4 (61.9–64.8)
Ethnicity (%)
Mexican 41.6 (38.6–44.6) 40.5 (39.5–41.4) 19.8 (17.1–22.5) 22.3 (21.1–23.5)
Cuban 18.6 (16.0–21.2) 20.5 (19.9–21.2) 24.5 (20.7–28.3) 24.7 (23.4–26.0)
Puerto Rican 11.9 (10.8–13.0) 14.4 (13.9–14.9) 31.5 (28.4–34.7) 37.3 (35.9–38.7)
Dominican 10.0 (8.7–11.2) 10.3 (9.8–10.7) 10.0 (8.1–11.9) 7.9 (6.8–9.1)
Central American 8.1 (7.0–9.2) 7.5 (6.9–8.1) 5.0 (4.1–6.0) 4.0 (3.6–4.3)
South American 5.7 (5.0–6.4) 3.7 (3.4–4.1) 3.6 (2.8–4.4) 1.7 (1.3–2.1)
Other or mixed 4.1 (3.5–4.7) 3.0 (2.7–3.4) 5.5 (4.4–6.7) 2.1 (1.8–2.4)
Height (cm) 164.0 (163.7–164.3) 162.1 (161.5–162.7) 164.0 (163.3–164.6) 161.0 (160.2–161.8)
WC (cm) 95.3 (94.8–95.7) 104.2 (103.4–105.0) 98.8 (97.5–100.0) 108.5 (106.8–110.1)
Smoking (pack-years) 4.1 (3.8–4.5) 7.4 (6.6–8.3) 6.4 (5.6–7.2) 14.5 (11.7–17.3)
HF (%) 0.8 (0.7–1.0) 3.9 (3.7–4.1) 1.8 (1.2–2.4) 7.6 (6.9–8.4)
CAD (%) 3.01 (2.46–3.56) 12.42 (10.16–14.69) 4.39 (3.22–5.56) 12.73 (9.59–15.88)
CRP (mg/L) 3.3 (3.1–3.5) 5.3 (4.9–5.7) 4.6 (4.1–5.2) 7.3 (6.3–8.3)
FEV1 (L) 3.2 (3.2–3.2) 2.6 (2.6–2.7) 3.0 (2.9–3.0) 2.2 (2.2–2.3)
FVC (L) 3.9 (3.9–4.0) 3.3 (3.2–3.4) 3.7 (3.7–3.8) 2.9 (2.8–3.0)
Dyspnea score 0.56 (0.52–0.60) 1.06 (0.96–1.16) 1.36 (1.23–1.50) 2.64 (2.42–2.85)
Data are mean (95% CI). Values are weighted for study design and nonresponse.
Table 2—Association among lung measures, HbA1c, and ACR
Variable Participants without lung disease Participants with lung disease
FEV1 (L)
HbA1c (%) 25.81 (6.76) 215.41 (13.4)
ACR (mg/g) 27 (2)+ 213 (4)+
FVC (L)
HbA1c (%) 215.93 (7.04)* 212.72 (13.96)
ACR (mg/g) 29 (2)+ 213 (5)*
Dyspnea score
HbA1c (%) 20.03 (0.02) 0.06 (0.05)
ACR (mg/g) 0.0002 (0.00006)* 0.0003 (0.0001)**
Data are mean (SE). The estimate is the increase in the mean FEV1 or FVC per 1% increase in
HbA1c and 100 mg/g increase in ACR, adjusting for age, sex, height, WC, Latino background,
cumulative smoking, and history of HF (for FEV1 and FVC) and CAD (for dyspnea score). *P ,
0.05; +P , 0.01; **P , 0.001.
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Linear regression analyses were used
to calculate adjusted means of lung
measures and to examine associations of
thesemeasureswithHbA1c andACR.Mod-
els were adjusted for age, sex, Hispanic/
Latino background, height, WC, cumula-
tive smoking, HF (for FEV1 and FVC), and
CAD (for dyspnea score). Age, height,WC,
CRP, and cumulative smoking were con-
tinuous variables, and the remaining var-
iableswere categorical. All statistical tests
were two-sided at a significance level of
0.05. All analyses were performed using
SAS 9.3 software (SAS Institute, Cary, NC).
RESULTS
Compared with participants without
DM, those with DM were older (54 vs.
38 years of age), more likely to be
women (54 vs. 51%) and Puerto Rican
(20 vs. 15%) and less likely to be South
American (3 vs. 5%), had larger WC
(105 vs. 96 cm), had more cumulative
smoking (8.8 vs. 4.4 pack-years), had a
higher level of systemic inflammation
(mean CRP 5.6 vs. 3.5 mg/L), and had a
higher prevalence of CAD (12.5 vs. 3.2%)
and HF (4.6 vs. 0.9%). Baseline charac-
teristics of the population by DM and
lung disease status are presented in
Table 1.
After adjustment for covariates, par-
ticipants with DM had lower mean FEV1
and FVC values and higher dyspnea
scores than those without DM (FEV1
3.00 [95% CI 2.96–3.04] vs. 3.10 [3.09–
3.11] L, P , 0.01, for participants with-
out lung disease and 2.86 [2.79–2.93] vs.
2.95 [2.92–2.99] L, P , 0.05, for partic-
ipants with lung disease; FVC 3.62
[3.59–3.66] vs. 3.81 [3.79–3.83] L, P ,
0.001, for participants without lung
disease and 3.56 [3.48–3.63] vs. 3.74
[3.70–3.77] L, P, 0.001, for participants
with lung disease; dyspnea score 0.60
[0.49–0.71] vs. 0.41 [0.34–0.49], P ,
0.001, for participants without lung
disease and 1.25 [0.94–1.55] vs. 0.77
[0.54–1.00], P , 0.001, for participants
with lung disease). Separate models
that adjusted for CRP did not change
the results (data not shown). Separate
analyses were performed that com-
pared outcomes variables (FEV1, FVC,
and dyspnea score) between partici-
pants without and with DM stratified
by age-groups (,45, 45–60, and .60
years old) and smoking status (never
and ever). Results showed that inde-
pendent of the age and smoking strata,
participants with DM had a higher im-
pairment in lung function and more
dyspnea than those without DM (Sup-
plementary Data).
In participants with DM, impairment
in all lung measures (FEV1, FVC, and
dyspnea score) correlated with ACR
(Table 2). FEV1 decreased by 7 6 2 and
136 4 mL per 100 mg/g increase in ACR
(P, 0.01 for both) in those without and
with lung disease, respectively. FVC de-
creased by 9 6 2 and 13 6 5 mL per
100 mg/g increase in ACR (P , 0.01
and P , 0.05, respectively) in partici-
pants without and with lung disease,
respectively. Dyspnea score increased
by 0.02 6 0.006 and 0.03 6 0.01 per
100 mg/g increase in ACR (P , 0.05 for
both) in those without and with lung
disease, respectively.
FVC inversely correlated with HbA1c
for participants with DM and without
lung disease (Table 2). FVC decreased
by 16 6 7 L per 1% increase in HbA1c
(P , 0.05).
Participants with DM were further
stratified into three groups based on
ACR (normo-, micro-, and macroalbumin-
uria) and mean FEV1, FVC, and dyspnea
score in each group and compared with
the group without DM and with nor-
moalbuminuria. For adults with DM
and macroalbuminuria versus without
DM and with normoalbuminuria, FVC
was 15% and 10% lower for participants
with and without lung disease, respec-
tively, and FEV1 was 6% lower and dysp-
nea score was 2.5-fold higher for both
lung disease groups. The impairment in
lung measures was twofold higher in in-
dividuals with DM and macroalbumin-
uria versus DM and microalbuminuria or
DM and normoalbuminuria (Table 3 and
Fig. 1).
CONCLUSIONS
In this large cohort of Hispanics/Latinos,
we found that individuals with DM have
lower FEV1 and FVC (withmore impaired
FVC than FEV1) and more dyspnea than
those without DM. The impairment in
all lung measures correlated with ACR
in participants with DM. Compared
with participants without DM and nor-
moalbuminuria, those with DM and
macroalbuminuria had much lower
FEV1 and FVC (with more impairment
in FVC) and more dyspnea. The negative
impact of DM on lung measures over-
all and stratified by albuminuria was
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present in participants without and with
lung disease (in particular, FVCwasmore
impaired in thosewith lung disease than in
those without lung disease).
The results generally are consistent
with those of prior cross-sectional stud-
ies that included Caucasian and African
American subjects and that demon-
strated lower FEV1 and FVC (with higher
impairment in FVC) in adults with DM
than in those without DM. Of note, al-
though in the Atherosclerosis Risk in
Communities study (1) FVC was 3.5%
lower in participants with DM versus
without DM (mean 3.74 [95% CI 3.71–
3.76] vs. 3.87 [3.86–3.88] L, P , 0.001),
in the current study, FVC was 5% lower
in those with DM versus without DM
(3.62 [3.59–3.66] vs. 3.81 [3.79–3.83] L,
P , 0.001). In both studies, the mean
FVC was similar in participants with-
out DM, and adjustment was performed
using similar confounders (age, sex,
height, smoking, central obesity); the
higher magnitude of impairment in
lung function in Hispanics/Latinos likely
is related to overall poorer glycemic
control and a higher rate and faster pro-
gression of microvascular complica-
tions compared with Caucasians and
African Americans. However, other
factors such as a genetic predisposition
could also play a role and requires fu-
ture investigation.
We evaluated the relationship be-
tween lung dysfunction and diabetic ne-
phropathy in individuals with DM. Lung
dysfunction correlated with ACR, and
the impairment in lung function was
twofold higher in participants with mac-
roalbuminuria than in those with micro-
or normoalbuminuria. Dyspnea score
mirrored lung dysfunction. These find-
ings suggest that lung dysfunction and
symptoms may increase as disease
worsens. Future studies should evaluate
the decline in lung function over time in
adults with DM and particularly in those
with poor glycemic control and faster
progression of microvascular complica-
tions. Detection of and prevention strat-
egies to limit lung function decline once
microalbuminuria is present should also
be investigated in future studies.
This study did not investigate the
mechanisms explaining lung dysfunc-
tion in DM, yet the correlation between
impaired lung function and ACR, which
was not affected by adjustment for
CRP, suggests that biological mecha-
nisms other than systemic inflammation
play a role in this association (24–26).
The results suggest that intrinsic lung
biological changes related to diabetic
microangiopathy causes lung dysfunc-
tion and symptoms.
The findings demonstrate a negative
effect of DM on lung measures not only
in individuals without lung disease but
also in those with preexisting lung dis-
ease. For these individuals, we found
that FVC is particularly more impaired
than in those without lung disease.
These findings have potential clinical
consequences. For instance, it is well
known that hyperglycemia predisposes
to pneumonia and chronic obstruc-
tive pulmonary disease exacerbations
(27). A potential explanation could be
hyperglycemia-induced impairment in
the chemotactic and bactericide pro-
perties of neutrophils (28). However, the
current results suggest that lung func-
tion impairment, particularly in adults
with advanced DM (and extensivemicro-
vascular complications), also contributes
to increasing respiratory morbidity in
adults with DM. In fact, this hypothesis
is supported by one of our prior clini-
cal studies, which demonstrated that pa-
tients with diabetes and impaired DLCO
had a higher odds of being hospitalized
with pneumonia independent of hyper-
glycemia and comorbidities (29). Future
studies should address whether tighter
targets for DM control in patients with
Figure 1—FEV1, FVC, and dyspnea score in participants with diabetes by ACR compared with those without diabetes. Ref, reference.
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lung disease limits DM-induced lung dys-
function and decreases respiratory mor-
bidity and mortality.
We found that individuals with DM
have more dyspnea than those without
DM. Although adults with DM have a
higher prevalence of CAD and HF (30)
and are expected to have more dyspnea
than those without DM (31), we demon-
strate that an intrinsic lung disease also
plays a role independent of other car-
diac etiologies. Strategies to limit not
only cardiac but also pulmonary origins
of dyspnea should be sought to improve
the respiratory and overall quality of life
in adults with DM.
The strengths of this study include a
community-based population, exten-
sive data on potential confounders,
and standardized spirometric tech-
niques. In contrast to prior studies, we
adjusted for cumulative smoking rather
than smoking status (32), WC rather
than BMI (33), and HF. We acknowledge
that basing HF on self-report rather than
on an objective measurement, such as
echocardiography, is a limitation. How-
ever, in a prior clinical study comparing
DLCO in patients with and without DM,
we adjusted for HF based on ICD-9 codes
in onemodel and a combination of ICD-9
codes and echocardiography criteria in a
second model (29). Adjusting not only
for clinical HF but also for asymptomatic
systolic and diastolic dysfunction did not
change the results (29).
The main limitation of this study is
related to its cross-sectional design. We
cannot establish the direction of associa-
tion between DM and lung dysfunction.
Prior longitudinal studies yielded con-
troversial results (7), but the majority
showed that lung function continued to
decline with DM progression. More-
frequent measurements and longer pe-
riods of follow-up are needed to better
characterize the progression of lung dys-
function in adults with DM. In addition, a
good characterization of the population,
which is prone to the development of
pulmonary microangiopathy and fibro-
sis, as well as a good understanding of
the progression of lung function decline
in DM are also needed before consider-
ing local therapeutic agents with poten-
tial proinflammatory properties, such as
inhaled insulin.
In summary, this study brings novel
findings to the literature. It shows that
Hispanics/Latinos with DM have lung
dysfunction that is likely more severe
than that of Caucasians and African
Americans; reports more lung-related
dyspnea in individuals with DM; demon-
strates a negative effect of DM on lung
function in individuals with lung dis-
eases such as asthma, chronic bronchi-
tis, and emphysema; and shows that
lung dysfunction and dyspnea in DM
correlate with other DM microvas-
cular complications, suggesting that
alveolar-capillary microangiopathy–
related mechanisms play a role in this
association.
Funding. The HCHS/SOL was carried out as a
collaborative study supported by contracts from
the National Heart, Lung, and Blood Institute to
the University of North Carolina (N01-HC-
65233), University of Miami (N01-HC-65234),
Albert Einstein College of Medicine (N01-
HC-65235), Northwestern University (N01-
HC-65236), and San Diego State University
(N01-HC-65237). The following National Insti-
tutes of Health institutes/offices collaborated
and cofunded the study: National Institute on
Minority Health and Health Disparities, National
Institute onDeafness andOther Communication
Disorders, National Institute of Dental and Cra-
niofacialResearch,National InstituteofDiabetes
and Digestive and Kidney Diseases, National
Institute of Neurological Disorders and Stroke,
and Office of Dietary Supplements.
Duality of Interest. No potential conflicts of
interest relevant to this article were reported.
Author Contributions. O.L.K. contributed to
the data research andwriting of themanuscript.
L.A.-S., H.R.C., A.M.K., R.C.K., G.L.K., E.M., L.S.,
G.T., andM.D. contributed to the discussion and
review and editing of the manuscript. J.C. and
D.W. contributed to the data analysis, discus-
sion, and review and editing of the manuscript.
O.L.K. is the guarantor of this work and, as such,
had full access to all the data in the study takes
responsibility for the integrityof thedataand the
accuracy of the data analysis.
References
1. Yeh HC, Punjabi NM, Wang NY, et al. Cross-
sectional and prospective study of lung function
in adults with type 2 diabetes: the Atheroscle-
rosis Risk in Communities (ARIC) study. Diabetes
Care 2008;31:741–746
2. Walter RE, Beiser A, Givelber RJ, O’Connor
GT, Gottlieb DJ. Association between glycemic
state and lung function: the Framingham Heart
Study. Am J Respir Crit CareMed 2003;167:911–
916
3. Lawlor DA, Ebrahim S, Smith GD. Associa-
tions of measures of lung function with insulin
resistance and type 2 diabetes: findings from
the British Women’s Heart and Health Study.
Diabetologia 2004;47:195–203
4. Chance WW, Rhee C, Yilmaz C, et al. Dimin-
ished alveolar microvascular reserves in type 2
diabetes reflect systemic microangiopathy. Di-
abetes Care 2008;31:1596–1601
5. Klein OL, Kalhan R, Williams MV, et al. Lung
spirometry parameters and diffusion capacity
are decreased in patients with type 2 diabetes.
Diabet Med 2012;29:212–219
6. Niranjan V, McBrayer DG, Ramirez LC, Raskin P,
Hsia CC. Glycemic control and cardiopulmonary
function in patients with insulin-dependent diabe-
tes mellitus. Am J Med 1997;103:504–513
7. Klein OL, Krishnan JA, Glick S, Smith LJ. Sys-
tematic review of the association between lung
function and type 2 diabetes mellitus. Diabet
Med 2010;27:977–987
8. van den Borst B, Gosker HR, Zeegers MP,
Schols AM. Pulmonary function in diabetes: a
metaanalysis. Chest 2010;138:393–406
9. Danaei G, Friedman AB, Oza S, Murray CJ,
Ezzati M. Diabetes prevalence and diagnosis in
US states: analysis of health surveys. Popul
Health Metr 2009;7:16–29
10. Ali MK, McKeever Bullard K, Imperatore G,
Barker L, Gregg EW; Centers for Disease Control
and Prevention (CDC). Characteristics associ-
ated with poor glycemic control among adults
with self-reported diagnosed diabetes–National
Health and Nutrition Examination Survey,
United States, 2007-2010. MMWRMorbMortal
Wkly Rep 2012;15(Suppl.):32–37
11. Wang Y, Katzmarzyk PT, Horswell R, et al.
Racial disparities in diabetic complications in an
underinsured population. J Clin Endocrinol
Metab 2012;97:4446–4453
12. Ehrlich SF, Quesenberry CP Jr, Van Den
Eeden SK, Shan J, Ferrara A. Patients diagnosed
with diabetes are at increased risk for asthma,
chronic obstructive pulmonary disease, pulmo-
nary fibrosis, and pneumonia but not lung can-
cer. Diabetes Care 2010;33:55–60
13. Rana JS, Mittleman MA, Sheikh J, et al.
Chronic obstructive pulmonary disease, asthma,
and risk of type 2 diabetes in women. Diabetes
Care 2004;27:2478–2484
14. Ward BW, Schiller JS, Goodman RA. Multi-
ple chronic conditions among US adults: a
2012 update. Prev Chronic Dis 2014;11:E62
15. Maters GA, de Voogd JN, Sanderman R,
Wempe JB. Predictors of all-cause mortality in
patients with stable COPD: medical comorbid
conditions or high depressive symptoms.
COPD 2014;11:468–474
16. Yang J, Tan Y, Zhao F, et al. Angiotensin II
plays a critical role in diabetic pulmonary fibro-
sis most likely via activation of NADPH oxidase-
mediated nitrosative damage. Am J Physiol
Endocrinol Metab 2011;301:E132–E144
17. Popov D, Simionescu M. Alterations of lung
structure in experimental diabetes, and diabe-
tes associated with hyperlipidaemia in ham-
sters. Eur Respir J 1997;10:1850–1858
18. Weynand B, Jonckheere A, Frans A, Rahier J.
Diabetes mellitus induces a thickening of the
pulmonary basal lamina. Respiration 1999;66:
14–19
19. Lavange LM, Kalsbeek WD, Sorlie PD, et al.
Sample design and cohort selection in the
Hispanic Community Health Study/Study of
Latinos. Ann Epidemiol 2010;20:642–649
20. Sorlie PD, Avile´s-Santa LM, Wassertheil-
Smoller S, et al. Design and implementation of
the Hispanic Community Health Study/Study of
Latinos. Ann Epidemiol 2010;20:629–641
21. Ferris BG Jr, Speizer FE, Bishop Y, Prang G,
Weener J. Spirometry for an epidemiologic
2056 Pulmonary Impairment in Hispanics With DM Diabetes Care Volume 39, November 2016
study: deriving optimum summary statistics for
each subject. Bull Eur Physiopathol Respir 1978;
14:145–166
22. ATS statementdSnowbird workshop on
standardization of spirometry. Am Rev Respir
Dis 1979;119:831–838
23. Mahler DA, Wells CK. Evaluation of clinical
methods for rating dyspnea. Chest 1988;93:
580–586
24. Festa A, D’Agostino R Jr, Howard G,
Mykka¨nen L, Tracy RP, Haffner SM; The Insulin
Resistance Atherosclerosis Study (IRIS). Chronic
subclinical inflammation as part of the insulin
resistance syndrome: the Insulin Resistance
Atherosclerosis Study (IRAS). Circulation 2000;
102:42–47
25. Barzilay JI, Abraham L, Heckbert SR, et al.
The relation of markers of inflammation to the
development of glucose disorders in the elderly:
the Cardiovascular Health Study. Diabetes 2001;
50:2384–2389
26. Hancox RJ, Poulton R, Greene JM, et al. Sys-
temic inflammation and lung function in young
adults. Thorax 2007;62:1064–1068
27. Labarere J, Stone RA, Obrosky DS, et al.
Comparison of outcomes for low-risk out-
patients and inpatients with pneumonia: a
propensity-adjusted analysis. Chest 2007;131:
480–488
28. Delamaire M, Maugendre D, Moreno M, Le
Goff MC, Allannic H, Genetet B. Impaired leuco-
cyte functions in diabetic patients. Diabet Med
1997;14:29–34
29. Klein OL, Smith LJ, Tipping M, Peng J,
Williams MV. Reduced diffusion lung capacity
in patients with type 2 diabetes mellitus pre-
dicts hospitalization for pneumonia. Diabetes
Res Clin Pract 2011;92:e12–e15
30. Piccini JP, Klein L, Gheorghiade M, Bonow
RO. New insights into diastolic heart failure: role
of diabetesmellitus. Am JMed2004;116(Suppl. 5A):
64S–75S
31. Guazzi M, Brambilla R, De Vita S, Guazzi
MD. Diabetes worsens pulmonary diffusion
in heart failure, and insulin counteracts this
effect. Am J Respir Crit Care Med 2002;166:
978–982
32. Strand BH, Mishra G, Kuh D, Guralnik JM,
Patel KV. Smoking history and physical perfor-
mance in midlife: results from the British
1946 birth cohort. J Gerontol A Biol Sci Med
Sci 2011;66:142–149
33. Wehrmeister FC, Menezes AM, Muniz LC,
Mart ı´nez-Mesa J, Domingues MR, Horta BL.
Waist circumference and pulmonary function:
a systematic review and meta-analysis. Syst
Rev 2012;1: 55
care.diabetesjournals.org Klein and Associates 2057
